Development and biological assessment of MMAE-trastuzumab antibody-drug conjugates (ADCs).

CONCLUSION: MMAE-trastuzumab ADCs represent a promising therapeutic strategy to treat HER2-positive breast cancer.
PMID: 32889587 [PubMed - as supplied by publisher]

Source: Breast Cancer - September 4, 2020 Category: Cancer & Oncology Authors: Yaghoubi S, Gharibi T, Karimi MH, Sadeqi Nezhad M, Seifalian A, Tavakkol R, Bagheri N, Dezhkam A, Abdollahpour-Alitappeh M Tags: Breast Cancer Source Type: research